GLG News by Restasis (Cyclosporine) Ophthalmic Emulsion Prescribers: Ophthalmologists (US)
Articles with lock require a subscription to GLG News |
Request a free trial
August 19, 2008Visian ICL: Premium Channel for the Extremely Nearsighted
Analysis of: Insiders Buy Staar as Lasik Alternate Shows Potential (Update2) | www.bloomberg.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
The Visian ICL (Implantable Collamer Lens) is an exquisitely precise technology for the correction of high degrees of nearsightedness -- much higher than the reach of laser refractive surgery such as LASIK and PRK. Given the price of the ICL and the intraocular surgey required for its...
July 21, 2008Ultimately, the Patient, Not the Payor, is the Customer
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
"He who pays the fiddler calls the tune." Here's an example of the fiddler pro-actively asking the guy in the room with the deepest pocket what he'd like to hear. If it's not something in the current repertoire, the fiddler seems willing to learn. However, by the time he's got...
May 7, 2008
LASIK IS AN EXCELLENT PROCEDURE FOR THE APPROPRIATE CANDIDATES
Analysis of: LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
Author: GLG Expert Contributor
LASIK IS AN EXCELLENT PROCEDURE FOR THE APPROPRIATE CANDIDATESAnalysis of: LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
Author: GLG Expert Contributor
The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years: Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone. About 1 out of 4 patients that consider lasik are actually good candidates...
May 6, 2008Doubts About LASIK
Analysis of: LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members. However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....
April 7, 2008
The Next Big Thing in Cataract and Lens Based Surgery: The Light Adjustable Lens (LAL)
Analysis of: Pilot trial for toric correction with light-adjustable lens yields promising early results | ophthalmologytimes.modernmedicine.com
Author: GLG Expert Contributor
The Next Big Thing in Cataract and Lens Based Surgery: The Light Adjustable Lens (LAL)Analysis of: Pilot trial for toric correction with light-adjustable lens yields promising early results | ophthalmologytimes.modernmedicine.com
Author: GLG Expert Contributor
The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery. The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...
January 29, 2008Bausch makes foray into presbyopic arena
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
Author: Barry Schechter, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc.
With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.
November 8, 2007
U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol ComboAnalysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...
October 31, 2007
GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION
Analysis of: Genentech revisits plan for Avastin | www.sfgate.com
Author: GLG Expert Contributor
GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATIONAnalysis of: Genentech revisits plan for Avastin | www.sfgate.com
Author: GLG Expert Contributor
In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is...
October 29, 2007
American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular Degeneration
Analysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin | aao.org
Author: GLG Expert Contributor
American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular DegenerationAnalysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin | aao.org
Author: GLG Expert Contributor
The American Academy of Ophthalmology said the recent decision by Genentech to limit availability of Avastin (bevacizumab) to compounding pharmacies could have a significant negative impact on the care of patients with age-related macular degeneration [AMD]. Dr. Charles Wilkinson, president of the AAO,...
October 22, 2007Mixing and Matching of IOLs Shows Strengths, Weaknesses
Analysis of: Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants | www.ncbi.nlm.nih.gov
Author: Mark Packer, Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Presbyopia correcting IOLs currently represent 5% of all IOLs implanted in the United States (about 3.5 million per year). The products available in this category include the ReSTOR multifocal IOL (Alcon), the ReZoom multifocal IOL (AMO) and the cyrstalens accommodative IOL (eyeonics). Although...
Page : 1 2 3 4 5 6 7 Next1 to 10 of 68
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008